Brokers Issue Forecasts for Vaxart, Inc.’s FY2022 Earnings (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT – Get Rating) – Analysts at Cantor Fitzgerald dropped their FY2022 earnings per share estimates for Vaxart in a report issued on Tuesday, May 17th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will post earnings of ($0.94) per share for the year, down from their previous estimate of ($0.85).

Vaxart (NASDAQ:VXRT – Get Rating) last issued its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Vaxart had a negative return on equity of 41.95% and a negative net margin of 16,892.57%.

Separately, Zacks Investment Research upgraded shares of Vaxart from a “sell” rating to a “hold” rating in a research note on Thursday, May 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Vaxart presently has a consensus rating of “Buy” and a consensus price target of $12.10.

NASDAQ:VXRT opened at $3.16 on Thursday. The firm has a market cap of $399.44 million, a P/E ratio of -4.94 and a beta of 0.67. Vaxart has a fifty-two week low of $2.49 and a fifty-two week high of $10.33. The firm has a 50-day simple moving average of $4.37 and a two-hundred day simple moving average of $5.38.

Several hedge funds and other institutional investors have recently made changes to their positions in VXRT. State Street Corp boosted its holdings in shares of Vaxart by 23.9% during the 1st quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company’s stock valued at $69,859,000 after acquiring an additional 2,673,332 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Vaxart by 87.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,126,924 shares of the biotechnology company’s stock valued at $13,335,000 after acquiring an additional 993,652 shares during the last quarter. Rafferty Asset Management LLC boosted its holdings in shares of Vaxart by 138.3% during the 4th quarter. Rafferty Asset Management LLC now owns 847,774 shares of the biotechnology company’s stock valued at $5,316,000 after acquiring an additional 492,066 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of Vaxart by 179.8% during the 4th quarter. Citigroup Inc. now owns 660,978 shares of the biotechnology company’s stock valued at $4,144,000 after acquiring an additional 424,746 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Vaxart by 539.9% during the 4th quarter. Bank of America Corp DE now owns 491,028 shares of the biotechnology company’s stock valued at $3,079,000 after acquiring an additional 414,297 shares during the last quarter. 45.91% of the stock is currently owned by hedge funds and other institutional investors.

Vaxart Company Profile (Get Rating)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

Featured Stories